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Background: Epigenetic alterations, such as aberrant DNA methylation of promoter and enhancer regions, which
lead to atypical gene expression, have been associated with carcinogenesis. In hepatocellular carcinoma (HCC),
genome-wide analysis of methylation has only recently been used. For a better understanding of
hepatocarcinogenesis, we applied an even higher resolution analysis of the promoter methylome to identify
previously unknown regions and genes differentially methylated in HCC.
Results: Optimized liquid hybridization capture-based bisulfite sequencing (LHC-BS) was developed to
quantitatively analyze 1.86 million CpG sites in individual samples from eight pairs of HCC and adjacent tissues. By
linking the differentially methylated regions (DMRs) in promoters to the differentially expressed genes (DEGs), we
identified 12 DMR-associated genes. We further utilized Illumina MiSeq combining the bisulfite sequencing PCR
approach to validate the 12 candidate genes. Analysis of an additional 78 HCC pairs on the Illumina MiSeq platform
confirmed that 7 genes showed either promoter hyper-methylation (SMAD6, IFITM1, LRRC4, CHST4, and TBX15) or
hypo-methylation (CCL20 and NQO1) in HCC.
Conclusions: Novel methylome profiling provides a cost-efficient approach to identifying candidate genes in
human HCC that may contribute to hepatocarcinogenesis. Our work provides further information critical for
understanding the epigenetic processes underlying tumorigenesis and development of HCC.
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article, unless otherwise stated.The development of HCC is a multistep process char-
acterized by the accumulation of genetic mutations and
epigenetic aberrations. Epigenetic alterations such as ab-
errant methylation and histone modification occur far
more frequently than genetic mutations in cancers and
can significantly affect the efficacy of messenger RNA
(mRNA) synthesis without changing the primary DNA
sequence [2]. Identification of specific DNA methylation
signatures thus has great potential to generate diagnostic
markers for early disease detection and further the de-
velopment of therapeutic regimens.
In mammalian cells, DNA methylation occurs at the
5′ position of the cytosine ring within CpG dinucleo-
tides, via the addition of a methyl group, to create a 5-
methylcytosine (m5C). DNA methylation sites tend tois distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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CpG Islands (CGIs) [3]. The two most common forms
of aberrant CpG methylation in cancer have been widely
studied, namely global hypo-methylation that causes
chromosomal instability and promoter hypo- or hyper-
methylation that leads to inappropriate activation of on-
cogenes or silencing of tumor suppressor genes (TSGs),
respectively [3, 4].
A number of powerful technologies have emerged in
recent years that allow high-throughput detection of
genome-wide epigenetic changes in HCC, furthering our
understanding of the impact of altered DNA methylation
on hepatocarcinogenesis [5–11]. For instance, promoter
microarray-based approaches include the methylated
CpG island amplification microarray chip (MCAM-chip)
that utilizes enzymatic digestion [5, 6] and the methylated
DNA immunoprecipitation microarray chip (MeDIP-chip)
that employs antibody pulldown [12] to enrich methylated
DNA. This is followed by profiling on a promoter array
and generally results in approximately 25,000 human pro-
moters being analyzed per sample. The second approach
relies on bead arrays, which are characterized by bisulfite
conversion of DNA followed by the use of a microbead-
based microarray. The highest throughput achieved by
this technique to date was the mapping of more than
485,000 CpG sites in HCC through an Infinium 450K
array [10, 11]. Studies that have utilized currently available
genome-wide profiling techniques have reported numer-
ous differentially methylated genes in HCC, including
tumor suppressor genes. Although many of the genes
identified in these investigations have differed, some con-
sistencies have been reported. For example, two studies
identified KLHL35, PAX5, PENK, and SPDYA to be hyper-
methylated in HCC of viral etiology [6, 9], while inde-
pendent studies have also found IGFALS [8, 13] and
MT1G [8, 13] to be repressed by hyper-methylation in
HCC. However, there still remains no general consensus
as to which genes consistently show differential methyla-
tion in HCC. In part, this may be due to intra- or inter-
tumor heterogeneity, differences between studies in the
etiology underlying the HCC, or differences in the tech-
nique and detection sites used, highlighting the necessity
for additional investigations to identify those genes that
most consistently show aberrant methylation. An import-
ant limitation of previous studies is that none have been
able to detect all CpG sites in the entire promoter regions
and thereby map the promoter methylome of human
HCC. In order to address this shortcoming, we have en-
hanced the coverage to include promoter regions genome-
wide and attempted to identify promising methylation
markers or characteristic driver genes that may not have
been reported previously in HCC.
We previously developed a liquid hybridization capture-
based bisulfite sequencing (LHC-BS) technique suitable forCpG methylation analysis using a massive parallel se
quencer-based approach, which relies on specific capture
of target regions by liquid hybridization. We demonstrated
that this approach could be used to examine the human
exome [14] as well as the promoter methylome [15]. In the
present study, we initially performed promoter-targeted
LHC-BS on eight paired HCC tissues to analyze 1.86 mil-
lion CpG sites located at the promoter regions of 31,372
(91.8 %) genes. Next, high-depth RNA-sequencing was ap-
plied to search for candidate genes in HCCs that showed a
negative correlation between gene expression and pro-
moter methylation. Illumina MiSeq combining the bisulfite
sequencing PCR approach was further carried out to valid-
ate these candidate genes in an additional 78 HCC tumor
and non-tumor pairs. Using this approach, we confirmed
that 7 genes showed altered promoter methylation in
HCC, with SMAD6, IFITM1, LRRC4, CHST4, and TBX15
exhibiting promoter hyper-methylation, and CCL20 and
NQO1 exhibiting promoter hypo-methylation. Western
blot and quantitative real time polymerase chain reaction
(qRT-PCR) experiments confirmed that a total of 5 genes
showed altered expression in HCC samples. Therefore,
LHC-BS-based promoter methylome analysis in HCC rep-
resents an effective technique for assessing epigenetic
changes across the human genome.
Results
The promoter methylome differentiates tumor tissue
from adjacent non-tumor tissue in HCC
The clinicopathologic features of the 8 patients with HCC
in this promoter-wide methylation study are described in
Additional file 1: Table S1. The primary etiology of this
group was HBV infection (7 of 8 patients). All patients had
a single tumor and most of the primary tumors (5 of 8)
had moderately differentiated histology; 6 of 8 had stage II
tumor, classified using the American Joint Committee on
Cancer (AJCC) TNM system.
A LHC-BS approach [14, 15] was subsequently applied to
profile the promoter methylome of the 8 sample pairs. Pro-
moters were denoted as regions from −2200 bp to +500 bp
of the transcriptional start sites (TSS) [16]. Based on the
hg19 reference human genome, a total of 150,407 capture
probes from the Crick strand were customized, capturing
1.86 million CpG nucleotides in the promoters. Based on
this design, the Watson strand can be captured, enabling a
coverage of 31,372 (91.8 %) genes in the RefSeq database
[15]. We obtained an average of 4.4 Gb clean data for each
sample, reaching 23× read depth, of which 94.77 % were
mapped to at least one genomic position, with 87.75 %
mapped uniquely to the reference genome. Furthermore,
94.21 % of the uniquely mapped reads were located at the
defined promoter regions (Additional file 2: Table S2). We
then filtered out all the CpG sites with less than 4×
coverage in the 8 paired samples. The median value of
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(1,685,393) sample was 1.374799 million CpGs.
To identify differential methylation of CpG loci linked
to HCC, we further picked 690,858 CpG sites achieving a
minimum read coverage of 4× in all 16 samples and per-
formed a hierarchical clustering analysis. Based on the
average level of methylation crossing downstream 500-bp
region around TSS, the tumor could be clearly separated
from adjacent non-tumor by significant changes in the
pattern of the promoter methylome (Fig. 1a). Principal
component analysis (PCA) consistently demonstrated that
HCC tissue exhibited greater variance than non-tumor tis-
sue, and this was further confirmed by chi-square tests
(Additional file 3: Figure S1A, B). These findings may sug-
gest generalized disruption of the integrity of the methy-
lome in HCC.
The promoter regions of genes losing or acquiring DNA
methylation show different CpG contents in HCC
To analyze the relationship between promoter DNA
methylation and activity determined by the CpG content of
the promoters, we applied a previously described classifica-
tion of promoters as having either high-CpG content
(HCP), intermediate CpG content (ICP), or low-CpG con-
tent (LCP), based on the CpG ratio, GC content, and length
of the CpG-rich region [16] (Additional file 4: Figure S2A).
In line with a previous report using MeDIP technology, our
analysis demonstrated that genes acquiring low DNA
methylation levels in tumors were mostly characterized by
the presence of HCP promoters (Additional file 4: FigureFig. 1 Hierarchical clustering analyses of the promoter methylomes of 8 pairs
DNA methylation levels of all promoters were used in the “Pvclust” algorithm
approximately unbiased (AU) P value and bootstrap probability (BP) P value, w
of the top 1000 CGIs containing highly variable methylations that were select
was calculated as sequenced reads number of C/sequenced reads number of
moderate methylation ratio, and green color indicates low methylation ratio. _
tissue samplesS2B). We further performed hierarchical clustering analyses
of CGIs, and a chi-square analysis was then applied to se-
lect the top 1000 genes containing highly variable CGI
methylations based on the P values (Fig. 1b). In general,
many of these 1000 genes had a substantially higher methy-
lation ratio in tumor tissue than in non-tumor tissue
(Fig. 1b). Interestingly, the majority of these 1000 CGIs
were consistently hypo-methylated in poorly differentiated
tumor (ID NO. 388) compared with moderately or well-
differentiated tumors. Although one tumor (ID NO. 734)
clustered closely with its adjacent tissue, we suspect that
this may have been due to contamination of the tumor
sample with non-tumor tissue. Overall, the data support
the possibility that enriched HCPs may be responsible for
inhibiting the expression of the corresponding genes.
Comparisons of promoter CpG methylation between HCC
tissue and adjacent tissue reveal differentially methylated
regions and DEGs
We next applied a pair-wise comparison to reveal differ-
entially methylated regions (DMRs). In each comparison,
the sliding window strategy was used to determine if the
region within the window exhibited differential methyla-
tion between tumor and non-tumor samples (Additional
file 5: Material and Methods). The approach generated
an average of 2972 DMRs for 16 samples, although there
was variation between sample pairs, suggesting high intra-
tumor heterogeneity in DNA methylation (Additional file
6: Figure S3B). However, 77 genes with one or two DMRs
were found in 6 of the 8 paired samples, and 67.5 % ofof HCC and adjacent non-tumor samples. a Clustering of the average
. Two types of P values (%) on the edge of the cluster are provided:
hich indicate how well the cluster is supported by the data. b Clustering
ed based on P values from a chi-square analysis. The methylation ratio
C + T. Red color indicates high methylation ratio, black color indicates
T denotes tumor tissue samples, and _N denotes non-tumor
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(Additional file 7: Table S3).
Promoter CGI methylation has frequently been associ-
ated with silencing of gene expression. To obtain expres-
sion data from the 8 HCC pairs, we used Illumina high-
throughput RNA-seq technology to assess differentially
expressed genes (DEGs). After removing low quality
reads, we obtained 84.55 % of reads aligned to previously
annotated genes, reaching 78.13 % of mapped unique
reads. Our analysis determined 18,850 genes exhibiting
at least one unique read. To identify DEGs, we next per-
formed a pair-wise comparison between tumor and non-
tumor tissue using a fold change cutoff of reads per kb
per million (RPKM) values larger than 2 and an FDR-
adjusted P value less than 0.01 [17]. Using this approach,
the median numbers of genes identified as DEGs for the
8 paired samples were 7019, and the majority showed
down-regulated expression in HCCs (Additional file 6:
Figure S3A). Only 93 DEGs were shared by 6 of the 8
paired samples (Additional file 8: Table S4).
We hypothesized that there would be a relationship
between the presence of DMRs in specific promoters
and the DEGs in the liver tumors. As a result, 24 genes
containing DMRs in promoter regions were subse-
quently matched and met the selection criteria in at least
5 of the 8 sample pairs (Additional file 9: Table S5).
Among these, 20 genes showed expression levels nega-
tively associated with the DMR methylation status.
These included 4 genes hypo-methylated in tumor tissue
(CLCNKA, BAIAP2L2, CCL20, and NQO1) and 16 genes
hyper-methylated in tumor tissue (IFITM1, SMAD6,
TBX15, CHST4, LRRC4, PHYHD1, STEAP4, TACSTD2,
NPC1L1,THRSP, KCNJ10, PALM3, FAM134B,TMEM100,
PM20D1, and GRHL2).
Selection of candidate genes and validation of
methylation in 78 pairs of HCCs by MiSeq-BSP
We further acquired an additional 78 paired samples (of
HCC and adjacent tissue) to validate the genes initially
identified in the LHC-BS study. Since most of the pri-
mary tumors studied in the LHC-BS analysis had a well
or moderately differentiated histology, we obtained 39
well-to-moderately and 39 moderately differentiated
HCCs together with their matched adjacent tissues
(Additional file 10: Table S6). The majority of the pa-
tients (96 %) in our study were male; the average age at
diagnosis and treatment of HCC was 47.6 ± 10.1 years;
88 % had HBV infection. With regard to the common
factors associated with HCC prognosis and recurrence,
83 % of the subjects had a single tumor, 65 % of the pri-
mary tumors were more than 5 cm in diameter, 58 % of
patients had stage III tumors, and 41 % of patients had
blood alpha-fetoprotein (AFP) levels greater than
4000 ng/ml. Therefore, the subjects represent a group ofpatients with hyper-vascular primary liver malignancy,
who have a poor prognosis, associated with large tumor
size as well as involvement of nearby or major vessels.
By undertaking a comprehensive literature search on
liver carcinogenesis, we manually selected 12 of these 20
genes showing an inverse relationship between promoter
methylation and gene expression. Among these 12
genes, 10 genes up-regulated in tumors with a hyper-
methylated promoter (IFITM1, SMAD6, TBX15, CHST4,
LRRC4, PHYHD1, STEAP4, TACSTD2, NPC1L1, and
THRSP) and 2 genes down-regulated in tumors with a
hypo-methylated promoter (CCL20 and NQO1) were
further validated using Illumina MiSeq sequencing-
based bisulfite sequencing PCR (MiSeq-BSP). Libraries for
the 12 genes were prepared and individually barcoded for
high-throughput pair-end sequencing using MiSeq2500
(Additional file 5: Material and Methods; Additional file 9:
Table S5). Deep-sequencing of individual PCR fragments
was achieved in a cost-effective way (Additional file 11:
Table S7). We found that 7 genes (IFITM1, SMAD6,
TBX15, CHST4, LRRC4, CCL20, and NQO1) showed sig-
nificantly different promoter methylation levels between
tumor and non-tumor tissue (P value < 0.001) in approxi-
mately 80 % of the 78 HCCs (Fig. 2a). In addition, 20–
40 % of the examined HCCs showed a minimal difference
in the mean values of 0.2 (corresponding to a 20 % differ-
ence in methylation) (Fig. 2b), indicating a highly tumor-
specific promoter methylome change in these genes.
We further performed supervised PCA on these 7
genes, which clearly separated tumors from non-
tumors (Fig. 2c). However, the methylation status of
these genes was not associated with any of the clinico-
pathologic findings, including histological differenti-
ation and TNM stage (Fig. 2d).
Validation of candidate gene expression in HCCs
Among the genes that exhibited aberrant methylation in
HCCs, SMAD6 has at least two transcript variants, the
full-length variant 1 (NM_005585.4) and the short vari-
ant 2 (NM_001142861.2). Genomic sequence alignment
suggested that the promoter hyper-methylation observed
occurred in the shorter spliced form, which lacks one in-
frame exon compared with the full-length transcript,
variant 1 (Fig. 3a). We further chose the primer pair spe-
cific for variant 2 and examined its expression in 8 HCC
pairs assessed by the LHC-BS assay. Through qRT-PCR
analysis, we confirmed reduced SMAD6 variant 2 mRNA
expressions in all examined tumors, indicating HCC-
specific down-regulation of variant 2 (Fig. 3b).
Western blot analysis was further performed on the 8
HCC pairs to confirm the protein expression of the can-
didate genes, including IFITM1, CHST4, TBX15, LRRC4,
and NQO1. Compared with adjacent non-tumor tissue,
we observed reduced protein expression of IFITM1 in 6
Fig. 2 Validation of recurrent methylation changes of 12 genes. a Violin plots of DMR methylation levels of 12 genes in 78 pairs of HCC and non-
tumor samples are shown. Differential methylation was tested using Student’s paired t test (***P value <0.001; *P value <0.05). b Distribution of
altered DNA methylation of 12 genes between 78 pairs of HCC and non-tumor samples. Four categories of methylation differences between HCC
and non-tumor samples are indicated. c Principal component analysis (PCA) of 7 validated genes in 78 pairs of HCC and non-tumor samples. d
PCA of 7 validated genes in 78 HCC samples
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decreased CHST4 amounts in 5 of 8 tumors (Fig. 3c, d).
However, we could not detect alterations in the protein
expressions of LRRC4 and NQO1 in HCC tissue (data
not shown).
Demonstration of epigenetic regulation of candidate
genes transcription via demethylation assays in cell lines
DNMT1 and DNMT3B, which belong to the DNA methyl-
transferase (DNMT) family, control DNA methylation. To
further evaluate the impact of promoter methylation on
gene expression, we utilized two cancer cell lines, namely
HCT116 wild type and HCT116DNMT1−/− DNMT3B−/−
double knockout (DKO) cells [18]. A total of 5 of 6 genes,
including CHST4, IFITM1, TBX15, LRRC4, and SMAD6
variant 2, showed high promoter methylation levels
(>80 %) in HCT116, while more than 50 % of their methy-
lation was lost in DKO cells as a consequence of DNMT
inhibition. Correspondingly, CCL20, CHST4, IFITM1, and
SMAD6 variant 2 showed elevated expression in HCT116DKO, confirmed by qRT-PCR (Fig. 4a and Additional
file 12: Table S8).
For hyper-methylated or transcriptionally silenced
genes, the DNA demethylating agent 5-aza-2-deoxycyti-
dine (DAC) is known to restore gene expression [19, 20].
We further analyzed candidate gene expression upon
DAC treatment in two immortalized non-tumor liver cell
lines (QSG-7701 and HL-7702) and two HCC cell lines
(HLE and HLF). For CCL20, we observed elevated expres-
sion in HCC cell lines upon treatment with DAC, but not
in non-tumor cell lines, suggesting that CCL20 methyla-
tion status may be specifically associated with HCC prog-
nosis. In agreement with the observations made in the
HCT116-DKO study, IFITM1 expression in HCC cell
lines was restored after treatment with DAC (Fig. 4b).
However, TBX15, LRRC4, and CHST4 showed no sys-
tematic difference in expression between HCC and
non-tumor liver cell lines (Additional file 13: Figure S4).
Nonetheless, these observations in cell lines do not ex-
clude the possibility that the expressions of TBX15 and
Fig. 3 Altered expression of the candidate genes in HCC tissues. a Schematic of the first five exons and two TSSs of SMAD6 together with the site of
the DMR. Methylation levels of CpGs within the DMR in HCC and non-tumor samples are displayed. b RT-PCR results of SMAD6 variant 2 in 8 pairs of
HCC and non-tumor samples used in the promoter-targeted LHC-BS study. Patient IDs are shown on the x-axis. Data are representative of three similar
experiments and displayed as mean ± SD. *P value <0.05; **P value <0.01, as evaluated using Student’s t test. c All 8 pairs of HCC samples were further
validated for the protein expression of candidate genes, including IFITM1, CHST4, and TBX15, by Western blot analysis (N non-tumor tissue, T tumor).
Patient IDs are shown above each panel. d Relative protein expression levels of IFITM1, TBX15, and CHST4 were normalized against actin and depicted
graphically. The results are representative of three independent experiments
Fig. 4 Demonstration of epigenetic regulation of candidate gene transcription. a Methylation and transcript expression levels of candidate genes in
HCT116 and DKO cell lines are shown. b Demethylation assay using DAC treatment; mRNA levels of CCL20 and IFITM1 were confirmed. For RT-PCR
results in b, the quantitative ratios were normalized to the expression of GAPDH. Data are representative of three similar experiments and displayed as
mean ± SD. *P value <0.05; **P value <0.01, as evaluated by Student’s t test
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promoter hyper-methylation, particularly as the West-
ern blot analysis of the 8 paired samples described
above revealed that TBX15 levels were reduced in 7 of
8 tumors, and CHST4 levels were decreased in 5 of 8
tumors (Fig. 3c, d).
Taken together, our results suggest that SMAD6 variant
2, IFITM1, TBX15, and CHST4 may act as TSGs in HCC
that are silenced by promoter hyper-methylation; mean-
while, CCL20 may be epigenetically activated in tumor
through promoter hypo-methylation, and elevated expres-
sion may be associated with a poor prognosis in HCC.
Discussion
HCC is a genetically heterogeneous disease. The goal of
genomic and epigenetic profiling efforts in studies of
HCC is to identify characteristic driver genes and im-
prove our understanding of the etiology of the disease.
Promoter CpG islands with aberrant hyper-methylation
are recognized as being an important mechanism for in-
activation of tumor-related suppressor genes in human
cancers. Although this has been extensively studied in
colon cancer, with many genes identified as harboring al-
tered methylation in their promoter CGIs [21], there is
currently far less information regarding HCC. Our previ-
ous study showed that the novel LHC-BS approach is a
reliable and efficient analytical platform for generating aFig. 5 Flow chart. Eight pairs of HCC samples were used to screen for candid
In HCC tissues, 2972 DMRs were determined and 77 genes with one or two D
expression was analyzed using the Illumina high-throughput RNA-seq techno
by 6 of the 8 paired samples. Through cross-matching DMR-containing genes
validation. Twelve candidate genes were validated for methylation and gene
performed in vitro, and 7 genes were identified as candidate genes in HCC, wsingle-base-pair resolution methylome map of promoter
regions in cancer and normal cell lines [14, 15]. In the
current study, we further optimized the technology to pro-
file the promoter methylome in 8 paired HCC samples.
The flow chart in Fig. 5 describes the strategy we used
to identify HCC-specific candidate genes. We first identi-
fied 77 genes with one or two DMRs shared by 6 of the 8
liver tumors and then detected 93 DEGs that were com-
mon to the tumors compared with non-tumor liver tissue
(Additional file 7: Table S3; Additional file 8: Table S4).
We further integrated these data and matched DEGs to
DMRs. The approach allowed us to characterize 20 genes
showing an inverse relationship between CpG methylation
and transcriptional activity. Although we found greater
heterogeneity in the DMR profiles among tumors as com-
pared with non-tumors, our findings further support the
idea that tumors in general have highly heterogeneous
DNA methylation patterns. As a result of the limited sam-
ple size and strict criteria, we excluded low quality vari-
ants. Therefore, it should not be surprising that the
current study has not yielded many overlapping candi-
date genes with altered promoter methylation. Indeed,
to focus on genes for which differential methylation
and expression could be related, we applied larger sam-
ple cohorts (78 paired HCC samples) for a further val-
idation using Illumina MiSeq-BSP (Fig. 2). Using this
approach, 7 genes were identified as undergoing tumor-ate methylation markers using the promoter-targeted LHC-BS approach.
MRs were found to be common in 6 of 8 paired samples. Gene
logy, and 7019 DEGs were detected. Among them, 93 DEGs were shared
with DEGs and searching the literature, 20 genes were selected for
expression in 78 paired HCC samples. Functional validation was
hose altered expression may contribute to hepatocarcinogenesis
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ing IFITM1, SMAD6, TBX15, CHST4, and LRRC4 with
hyper-methylated promoters and CCL20 and NQO1
with hypo-methylated promoters.
We subsequently confirmed the correlation between
promoter methylation and expression levels of the
SMAD6, IFITM1, TBX15, CHST4, and CCL20 genes
(Figs. 3 and 4). In particular, we found that IFITM1
showed significantly down-regulated expression with ab-
normal epigenetic regulation in HCC. IFITM1 encodes
an interferon (IFN)-induced antiviral protein that plays a
key role in IFN-gamma mediated anti-proliferation
either by inhibiting ERK activation or inducing p53-
dependent G1 arrest [22]. The down-regulation of
IFITM1 has been linked to both low-grade diffuse astro-
cytomas and breast cancer [23, 24]. In addition, epigenetic
silencing of the IFITM1 protein has been found in other
human malignancies, including gastric cancer [25]. Given
that IFN-gamma plays a role during HCC immunotherapy
and has a direct inhibitory effect on HCC by inducing
apoptosis, future studies will be focused on understanding
whether IFITM1 suppresses HCC through IFN-gamma sig-
nal transduction.
Another TSG candidate highlighted is the short tran-
script of SMAD6, variant 2, but not the full-length
SMAD6, variant 1. SMAD transcription factors lie at
the core of the transforming growth factor-beta (TGF-β)
signaling pathway. Recent studies have suggested that
differentially spliced forms of many SMAD family
members are generated by genetic or epigenetic inacti-
vation and may represent an important step in neoplas-
tic transformation [26–28]. As noted, tumor-derived
variants of SMADs often carry a mutated N- or C-
domain, which inhibits the formation of homodimers
or heterodimers with other SMADs, resulting in a loss
of sensitivity to TGF-β cytokine family-mediated
growth arrest [26, 27]. Unlike SMAD6 variant 1, which
is broadly expressed and functions as a negative regula-
tor of bone morphogenetic protein (BMP) and TGF-β
signaling [29], variant 2 has a truncated MAD hom-
ology (MH)-1 domain and is variably expressed. It has
been reported that variant 2 forms non-productive het-
erodimers with SMAD7 in a transcriptional complex,
thereby, interfering with conventional BMP/TGF-β1
signaling [30]. Additional studies are required to deter-
mine whether silencing SMAD6 variant 2 may contrib-
ute to HCC tumorigenesis.
Treatment of HCC cell lines with DAC was associated
with CCL20 promoter hypo-methylation together with
elevated expression (Fig. 4). Up-regulated CCL20 expres-
sion is observed in many tumors including HCC [31].
The oncogenic role of CCL20 has been characterized to
be the promotion of tumor cell invasion through the up-
regulation of MMP-9 in colorectal cancer cells andpancreatic adenocarcinoma [32, 33]. Our findings sug-
gest that the presence of CCL20 in the tumor may indi-
cate a poor prognosis of HCC. Further studies are
required to completely understand the epigenetic and
molecular mechanisms regulating CCL20 expression and
determine whether it plays a role in metastasis in ad-
vanced HCC.
However, HBV infection is the major risk factor for
HCC in China. In this study, 7 of 8 patients were in-
fected with HBV, including tumor and adjacent liver tis-
sues (primarily cirrhotic). The current study could not
confirm an association of these genes with HBV infec-
tion and HBV-induced HCC tumorigenesis. Further
studies are warranted to clarify these issues.
Conclusions
In summary, to the best of our knowledge, this is the
first report to apply promoter-targeted LHC-BS technol-
ogy to assessing the promoter methylome in HCC at a
single-base resolution. Our current analysis focused on
differential methylation patterns in or near gene pro-
moters. In combination with RNA-seq and gene expres-
sion data, this technique allows for the identification of
promising tumor suppressor and oncogene candidates in
human HCC. Our work highlights the potential of cost-
efficient epigenetic approaches in the prevention and
therapy of human HCC.
Methods
Patients and specimens
This study was approved by the Institutional Review
Board of Tongji Hospital, Tongji Medical College of
Huazhong University of Science and Technology (HUST)
and the local ethics committee in Hubei province, China.
All patients included in the study were referred for treat-
ment at Tongji Hospital between 2008 and 2012. Written
informed consent was obtained from each patient. The
histological diagnosis and classification of HCC and adja-
cent liver tissue (primarily cirrhotic) were performed by
experienced pathologists. Information about risk factors
and other clinicopathologic characteristics for HCC was
retrieved from medical records. Among these, HBV (hepa-
titis B surface antigen; HBsAg) and HCV (anti-HCV) sta-
tuses were determined by immunoassays.
Promoter-targeted LHC-BS and RNA-seq
Promoter-targeted LHC-BS was performed as described
previously [15]. Briefly, 1 μg DNA per sample was proc-
essed by fragmentation, blunt end repair, 3′adenylation,
and 5′-methylcytosine index adapter ligation. Then,
250 ng DNA from each offer adapter-ligated libraries were
pooled together for the liquid hybridization capture pro-
cedure. We applied capture program, bisulfite treatment,
and PCR amplification based on previous protocols [15].
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purified using Oligo(dT) Beads (Illumina), and this was
followed by fragmentation. The converted double-
stranded cDNA product was subjected to blunt-ending,
dA addition to the 3′ end and adapter ligation. The
adapter-ligated fragments were size selected (200 ± 20 bp)
using 2 % TAE–Certified Low-Range Ultra Agarose (Bio-
Rad). After purification, 15 rounds of PCR amplification
were performed to enrich the adapter-ligated cDNA li-
braries. The LHC-BS and RNA-seq libraries were per-
formed on an Agilent Technologies 2100 Bioanalyzer
using the Agilent DNA 1000 chip kit. They were subse-
quently quantified on a StepOne plus qPCR, and library
products were sequenced using the Illumina Hiseq2000.
Computational processing of the next-generation
sequencing data
See Additional file 5: Materials and Methods.
5′-aza-2′-Deoxycytidine treatment of cell lines
Two human HCC cell lines (HLE and HLF) and 2 im-
mortalized liver cell lines (QSG-7701 and HL-7702)
were cultured at 5 % CO2, 37 °C, and 95 % humidity in
Dulbecco’s modified Eagle medium (DMEM; Gibco-Life
Technologies) supplemented with 10 % fetal bovine
serum (FBS; Gibco; Life Technologies), 100 units/mL
penicillin, and 100 μg/mL streptomycin (Sigma-Aldrich).
After growing to about 60 % confluency, cells were
treated with 5 μM DAC (Sigma) for 72 h. DAC was
replenished every 24 h. After 72 h, DAC-treated cells
and untreated controls were harvested.
Illumina MiSeq sequencing-based bisulfite sequencing
PCR
See Additional file 5: Materials and Methods, and
Additional file 11: Table S7.
Quantitative real-time PCR
Reverse transcribed with ReverTra Ace-α-™ (Toyobo) was
1 μg of total RNA. qRT-PCR was carried out using TaqMan
Universal Master Mix II with UNG on an ABI StepOne
Real-Time PCR System (Applied Biosystems, USA). The
relative RNA expression was calculated using the delta delta
threshold cycle (ΔΔCT) method and normalized to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) ex-
pression. Each assay was performed in triplicate.
Western blot
Western blot was performed with antibodies specific to
IFITM1 (mouse monoclonal antibody 1:2000, Proteintech
Group, USA), TBX15 (rabbit polyclonal antibody 1:1000,
Aviva Systems Biology, USA), CHST4 (rabbit polyclonal
antibody 1:1000, Aviva Systems Biology), LRRC4 (rabbit
polyclonal antibody 1:1000, Abgent, USA), and NQO1(mouse monoclonal antibody 1:1000, Santa Cruz Biotech-
nology, USA). β-actin (mouse monoclonal antibody
1:10,000, Santa Cruz Biotechnology) was used as a loading
control. The expression levels of the proteins were quanti-
fied by ChemiDoc™ MP Imager Universal hood III (Bio-
Rad Laboratories Inc., USA).
Statistical analysis
All differential methylation analyses were performed using
M values, and β values, ranging from 0 to 100 % methyla-
tion. Differential methylation was tested statistically using
Student’s paired t test. CpG sites with FDR <0.05 and a
within-pair methylation difference of ≥5 % were considered
differentially methylated. Moderated t statistics with the
Benjamini and Hochberg (BH) correction methods were
used to compare within-pair differences of tumor and non-
tumor pairs between groups, to examine whether the iden-
tified within-pair methylation discordances were group
specific. Hierarchical clustering analyses were performed
on the promoter methylomes of paired samples. Clustering
of average DNA methylation levels of all promoters were
used in the “Pvclust” algorithm. Two types of P values (%)
on the edge of the cluster are provided: approximately un-
biased (AU) and bootstrap probability (BP) P values. The
top 1000 CGIs containing highly variable methylations
were selected based on P values from a chi-square analysis.
R and Stata statistical software (release 12.0; Stata Corpor-
ation, USA) were used for statistical analysis.
Gene set and pathway analyses
The significance of predefined sets of CpGs, each set repre-
senting a pathway on KEGG, was analyzed by the R pack-
age GSA. GSA was applied on within-pair differences in
methylation and run with 1000 permutations. An FDR cut-
off of 0.1 and a P value cutoff of 0.05 were considered sig-
nificant IPA (Ingenuity Systems, Redwood City, CA, USA),
with KEGG pathways used to generate gene networks and
functions in HCC tumorigenesis and development.
Data and material availability
All raw and processed data of promoter LHC-BS and
RNA-Seq have been deposited in NCBI’s Gene Expression
Omnibus (GEO) with accession reference GSE55759.
Additional files
Additional file 1: Table S1. Clinicopathology features of patients with
HCC studied for genome-wide promoter methylation analysis.
Additional file 2: Table S2. Data generation for LHC-BS and RNA-Seq.
Additional file 3: Figure S1. Tumors are separated from adjacent non-
tumors through analysis of the patterns of the promoter methylomes. A,
principal component analysis (PCA) of the average methylation levels of
total promoters in 8 pairs of HCCs and non-tumor samples; B, cumulative
curves of –log(P value) from the chi-square test on intra-group variations
of CpG methylation levels in HCC tumors (T) and non-tumors (N).
Gao et al. Clinical Epigenetics  (2015) 7:86 Page 10 of 11Additional file 4: Figure S2. Promoter classification based on CpG
representation. A, the histograms represent the distribution of observed
versus expected CpG frequencies for all promoters, displaying the low
(LCPs, red), intermediate (ICPs, green), and high (HCPs, blue) CpG content
promoters; B, the proportion of the three categories of promoters.
Additional file 5: Materials and Methods. Computational processing
of the next-generation sequencing data; Illumina MiSeq sequencing-
based bisulfite sequencing PCR (MiSeq-BSP).
Additional file 6: Figure S3. Percentage of DEGs and DMR-containing
genes determined in 8 paired HCC tissues. A, counts of down- and up-
regulated genes in HCCs in comparison with non-tumors; B, counts of
hyper- and hypo-methylated genes in HCCs in comparison with non-
tumor tissue.
Additional file 7: Table S3. Summary of 77 genes containing DMRs
across at least 6 pairs of HCCs and non-tumors by LHC-BS.
Additional file 8: Table S4. Summary of 93 DEGs shared by at least 6
paired HCC tissues.
Additional file 9: Table S5. Summary of 20 genes showing negative
correlation between methylation and gene expression in at least 5 out of
8 pairs of samples.
Additional file 10: Table S6. Clinicopathological features of 78 Chinese
HCC patients studied for validation of gene expression.
Additional file 11: Table S7. Primer sequences for MiSeq-BSP and RT-
PCR validation.
Additional file 12: TableS8. Coverage and methylation levels of 12
genes validated by MiSeq-BSP.
Additional file 13: FigureS4. RT-PCR results for TBX15, LRRC4 and
CHST4 in a demethylation assay. The quantitative ratios were normalized
to the expression of GAPDH. Data are representative of three similar
experiments and displayed as mean ± SD. *, P <0.05 as evaluated by
Student’s t test.
Abbreviations
AFP: alpha-fetoprotein; BMP: bone morphogenetic protein; CGI: CpG Islands;
DAC: 5-aza-2-deoxycytidine; DEG: differentially expressed genes;
DMR: differentially methylated regions; DNMTs: DNA methyltransferases;
HBV: Hepatitis B virus; HCC: hepatocellular carcinoma; HCP: high-CpG
promoters; HCV: Hepatitis C virus; ICP: intermediate-CpG promoters;
LCP: low-CpG promoters; LHC-BS: liquid hybridization capture-based bisulfite
sequencing; MH: MAD homology; MiSeq-BSP: MiSeq sequencing-based
bisulfite sequencing PCR; PCA: principal component analysis; RPKM: reads per
kb per million; TSG: tumor suppressor gene.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
The experiments were conceived and designed by FG and QC. The
experiments were performed by HFL, JWW, and MX. The data were analyzed
and interpreted by FG, HFL, ZMY, YY, TW, and XLT. HX, JJY, WX, WC, and MZ
participated in the conduction and coordination of the study, including
providing cell lines and reagents, acquiring and managing patients, and
providing facilities. The study was supervised by XQZ, QC and XPC. The
manuscript was written by FG, AL, and QC. All authors read and approved
the final manuscript.
Acknowledgements
We are grateful to all the staff of the Hepatic Surgery Center at Tongji
Hospital in Wuhan for providing valuable samples and clinical information.
The authors thank Arian Laurence at the Newcastle upon Tyne Hospitals
NHS Foundation Trust and Massimo Gadina at National Institute of Health for
English language editing. The authors would like to acknowledge the
following funding sources: the Major and Special Program of National
Science and Technology in Twelfth Five-year Plan of China
(2012ZX10002016-004, 2012ZX10002010-001-004, XPC), Major Science
Foundation of the Ministry of Health of China (201302009, XPC), National
Natural Science Foundation of China (31200666, 81471612, QC; 81202300,HFL and 81372495, XPC), Chinese 863 Program (2012AA02A201, XQZ), and
Innovative R&D Team Program of Guangdong Province (2009010016, XQZ).
Author details
1Hepatic Surgery Centre, Tongji Hospital, Tongji Medical College, Huazhong
University of Science and Technology, Wuhan 430030 Hubei, China. 2Science
& Technology Department, BGI-Shenzhen, Shenzhen 518083 Guangdong,
China. 3Division of Gastroenterology, Department of Internal Medicine, Tongji
Hospital, Tongji Medical College, Huazhong University of Science and
Technology, Wuhan 430030 Hubei, China. 4The Newcastle upon Tyne
Hospitals NHS Foundation Trust, Freeman Hospital, Freeman Road, High
Heaton, Newcastle upon Tyne NE7 7DN, UK. 5Department of Urology, Tongji
Hospital, Tongji Medical College, Huazhong University of Science and
Technology, Wuhan 430030 Hubei, China. 6Translational Medicine Center,
Tongji Hospital, Tongji Medical College, Huazhong University of Science and
Technology, Wuhan 430030 Hubei, China.
Received: 5 May 2015 Accepted: 3 August 2015References
1. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD.
Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis.
World J Gastroenterol. 2008;14(27):4300–8.
2. Consortium EP, Bernstein BE, Birney E, Dunham I, Green ED, Gunter C, et al.
An integrated encyclopedia of DNA elements in the human genome.
Nature. 2012;489(7414):57–74. doi:10.1038/nature11247.
3. Plass C. Cancer epigenomics. Hum Mol Genet. 2002;11(20):2479–88.
4. Tischoff I, Tannapfe A. DNA methylation in hepatocellular carcinoma. World
J Gastroenterol. 2008;14(11):1741–8.
5. Gao W, Kondo Y, Shen L, Shimizu Y, Sano T, Yamao K, et al. Variable DNA
methylation patterns associated with progression of disease in
hepatocellular carcinomas. Carcinogenesis. 2008;29(10):1901–10. doi:10.1093/
carcin/bgn170.
6. Shitani M, Sasaki S, Akutsu N, Takagi H, Suzuki H, Nojima M, et al. Genome-
wide analysis of DNA methylation identifies novel cancer-related genes in
hepatocellular carcinoma. Tumour Biol. 2012;33(5):1307–17. doi:10.1007/
s13277-012-0378-3.
7. Hernandez-Vargas H, Lambert MP, Le Calvez-Kelm F, Gouysse G, McKay-
Chopin S, Tavtigian SV, et al. Hepatocellular carcinoma displays distinct DNA
methylation signatures with potential as clinical predictors. PLoS One.
2010;5(3):e9749. doi:10.1371/journal.pone.0009749.
8. Neumann O, Kesselmeier M, Geffers R, Pellegrino R, Radlwimmer B,
Hoffmann K, et al. Methylome analysis and integrative profiling of human
HCCs identify novel protumorigenic factors. Hepatology. 2012;56(5):1817–27.
doi:10.1002/hep.25870.
9. Shen J, Wang S, Zhang YJ, Kappil M, Wu HC, Kibriya MG, et al. Genome-
wide DNA methylation profiles in hepatocellular carcinoma. Hepatology.
2012;55(6):1799–808. doi:10.1002/hep.25569.
10. Shen J, Wang S, Zhang YJ, Wu HC, Kibriya MG, Jasmine F, et al. Exploring
genome-wide DNA methylation profiles altered in hepatocellular carcinoma
using Infinium HumanMethylation 450 BeadChips. Epigenetics. 2013;8(1):34–43.
doi:10.4161/epi.23062.
11. Song MA, Tiirikainen M, Kwee S, Okimoto G, Yu H, Wong LL. Elucidating the
landscape of aberrant DNA methylation in hepatocellular carcinoma. PLoS
One. 2013;8(2):e55761. doi:10.1371/journal.pone.0055761.
12. Stefanska B, Huang J, Bhattacharyya B, Suderman M, Hallett M, Han ZG, et al.
Definition of the landscape of promoter DNA hypomethylation in liver cancer.
Cancer Res. 2011;71(17):5891–903. doi:10.1158/0008-5472.CAN-10-3823.
13. Udali S, Guarini P, Ruzzenente A, Ferrarini A, Guglielmi A, Lotto V, et al. DNA
methylation and gene expression profiles show novel regulatory pathways
in hepatocellular carcinoma. Clin Epigenetics. 2015;7(1):43.
doi:10.1186/s13148-015-0077-1.
14. Wang J, Jiang H, Ji G, Gao F, Wu M, Sun J, et al. High resolution profiling of
human exon methylation by liquid hybridization capture-based bisulfite
sequencing. BMC Genomics. 2011;12:597. doi:10.1186/1471-2164-12-597.
15. Gao F, Wang J, Ji G, Liu S, Yao Y, Wang T et al. Clustering of cancer cell lines
using a promoter-targeted liquid hybridization capture-based bisulfite
sequencing approach. Technol Cancer Res Treat. 2014. doi:10.7785/
tcrt.2012.500416.
Gao et al. Clinical Epigenetics  (2015) 7:86 Page 11 of 1116. Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, Rebhan M, et al.
Distribution, silencing potential and evolutionary impact of promoter DNA
methylation in the human genome. Nat Genet. 2007;39(4):457–66.
doi:10.1038/ng1990.
17. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and
quantifying mammalian transcriptomes by RNA-Seq. Nat Methods.
2008;5(7):621–8. doi:10.1038/nmeth.1226.
18. Wang J, Xia Y, Li L, Gong D, Yao Y, Luo H, et al. Double restriction-enzyme
digestion improves the coverage and accuracy of genome-wide CpG
methylation profiling by reduced representation bisulfite sequencing. BMC
Genomics. 2013;14:11. doi:10.1186/1471-2164-14-11.
19. Hagemann S, Heil O, Lyko F, Brueckner B. Azacytidine and decitabine
induce gene-specific and non-random DNA demethylation in human
cancer cell lines. PLoS One. 2011;6(3):e17388.
doi:10.1371/journal.pone.0017388.
20. Tao SF, Zhang CS, Guo XL, Xu Y, Zhang SS, Song JR, et al. Anti-tumor effect
of 5-aza-2′-deoxycytidine by inhibiting telomerase activity in hepatocellular
carcinoma cells. World J Gastroenterol. 2012;18(19):2334–43. doi:10.3748/
wjg.v18.i19.2334.
21. Wang X, Kuang YY, Hu XT. Advances in epigenetic biomarker research in
colorectal cancer. World J Gastroenterol. 2014;20(15):4276–87.
doi:10.3748/wjg.v20.i15.4276.
22. Yang G, Xu Y, Chen X, Hu G. IFITM1 plays an essential role in the
antiproliferative action of interferon-gamma. Oncogene. 2007;26(4):594–603.
doi:10.1038/sj.onc.1209807.
23. Huang H, Colella S, Kurrer M, Yonekawa Y, Kleihues P, Ohgaki H. Gene
expression profiling of low-grade diffuse astrocytomas by cDNA arrays.
Cancer Res. 2000;60(24):6868–74.
24. Abba MC, Drake JA, Hawkins KA, Hu Y, Sun H, Notcovich C, et al.
Transcriptomic changes in human breast cancer progression as determined
by serial analysis of gene expression. Breast Cancer Res. 2004;6(5):R499–513.
doi:10.1186/bcr899.
25. Lee J, Goh SH, Song N, Hwang JA, Nam S, Choi IJ, et al. Overexpression of
IFITM1 has clinicopathologic effects on gastric cancer and is regulated by
an epigenetic mechanism. Am J Pathol. 2012;181(1):43–52. doi:10.1016/
j.ajpath.2012.03.027.
26. Jiang Y, Liang H, Guo W, Kottickal LV, Nagarajan L. Differential expression of
a novel C-terminally truncated splice form of SMAD5 in hematopoietic stem
cells and leukemia. Blood. 2000;95(12):3945–50.
27. Hata A, Lo RS, Wotton D, Lagna G, Massague J. Mutations increasing
autoinhibition inactivate tumour suppressors Smad2 and Smad4. Nature.
1997;388(6637):82–7. doi:10.1038/40424.
28. Cheng KH, Ponte JF, Thiagalingam S. Elucidation of epigenetic inactivation
of SMAD8 in cancer using targeted expressed gene display. Cancer Res.
2004;64(5):1639–46.
29. Imamura T, Takase M, Nishihara A, Oeda E, Hanai J, Kawabata M, et al.
Smad6 inhibits signalling by the TGF-beta superfamily. Nature.
1997;389(6651):622–6. doi:10.1038/39355.
30. Topper JN, Cai J, Qiu Y, Anderson KR, Xu YY, Deeds JD, et al. Vascular MADs:
two novel MAD-related genes selectively inducible by flow in human
vascular endothelium. Proc Natl Acad Sci U S A. 1997;94(17):9314–9.
31. Soliman HH, Nagy H, Kotb N, Alm El-Din MA. The role of chemokine CC
ligand 20 in patients with liver cirrhosis and hepatocellular carcinoma.
Int J Biol Markers. 2012;27(2):e125–31. doi:10.5301/JBM.2012.9097.
32. Campbell AS, Albo D, Kimsey TF, White SL, Wang TN. Macrophage
inflammatory protein-3alpha promotes pancreatic cancer cell invasion.
J Surg Res. 2005;123(1):96–101. doi:10.1016/j.jss.2004.07.013.
33. Brand S, Olszak T, Beigel F, Diebold J, Otte JM, Eichhorst ST, et al. Cell
differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and
Akt signaling resulting in proliferation and migration of colorectal cancer
cells. J Cell Biochem. 2006;97(4):709–23. doi:10.1002/jcb.20672.
34. Gao F, Liu X, Wu XP, Wang XL, Gong D, Lu H, et al. Differential DNA methylation
in discrete developmental stages of the parasitic nematode Trichinella spiralis.
Genome Biol. 2012;13(10):R100. doi:10.1186/gb-2012-13-10-r100.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
